HCPLive highlighted an analysis of the Phase 3 METREX, METREO and MATINEE trials by Gerard J. Criner, MD, FACP, FACCP, Director of the Temple Lung Center, and colleagues which found that across patients with chronic obstructive pulmonary disease (COPD) and evidence of type 2 inflammation, mepolizumab consistently reduced the annualized rate of moderate or severe exacerbations compared with placebo, regardless of blood eosinophil count (BEC) variability pattern. The analysis, which was presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting, supports the use of mepolizumab in patients with inadequately controlled COPD and documented type 2 inflammatory activity and suggests that requiring persistent eosinophilia may unnecessarily exclude patients who could achieve meaningful risk reduction.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH